Home > Insider Trading > Filing (0000899243-20-010812)

Filing Details

Accession Number:: 0000899243-20-010812
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-04-15 21:04:05
Reporting Period:: 2020-04-13

Accepted Time:: 2020-04-15 21:04:05
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1367644	Emergent Biosolutions Inc.	EBS	Pharmaceutical Preparations (2834)	141902018

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1380185	Fuad El-Hibri	400 Professional Drive, Suite 400 Gaithersburg MD 20879	Chairman	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2020-04-13	17,071	$62.25	1,348,321	No	4	S	Direct
Common Stock	Disposition	2020-04-14	6,261	$62.99	1,342,060	No	4	S	Direct
Common Stock	Disposition	2020-04-15	12,537	$62.58	1,329,523	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,344,250	Indirect	By Intervac, L.L.C.
Common Stock	1,524,155	Indirect	By Biovac, L.L.C.

Footnotes

These transactions were made by the Reporting Person pursuant to a trading plan adopted by the Reporting Person on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 ("Rule 10b5-1(c)").
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.62 to $63.00.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.53 to $63.66.
The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c).
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.62 to $63.29.
Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.